Chad Robins, CEO of Adaptive Biotechnologies.
Anjali Sundaram | CNBC
Ark Invest analyst Simon Barnett on Monday explained the firm’s approach to what it calls the genomic revolution.
In an interview on CNBC’s “Closing Bell”, Barnett said that Ark Invest led by Cathie Wood sees great potential for investors in the branch of molecular biology, known as genomics, and that it’s one of the most transformative investment opportunities. of the century ‘.
Ark’s family of funds includes the Genomic Revolution ETF (ARKG), which seeks to provide investors with exposure to areas such as DNA sequencing technology and molecular diagnostics.
ARKG is about 7% lower so far.
In the last 12 months, however, the ETF has risen about 160%. The firm’s flagship fund is the Ark Innovation ETF (ARKK), which has fallen by about 1.6% so far in 2021. ARKK has also risen by almost 160% in the last twelve months.